Global Gene Therapy Partnering Terms and Agreements 2010 to 2022


The Global Gene Therapy Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2022
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Gene Therapy Partnering Agreements 2010-2022 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in gene therapy partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Gene therapypartnering contract documents
  • Top gene therapy deals by value


The Global Gene Therapy Partnering Terms and Agreements 2010-2022 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 


This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.  


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 650 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


The initial chapters of this report provide an orientation of gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2010. The chapter is organized by specific gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by gene therapy partnering company A-Z, deal type definitions and gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in gene therapy partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gene therapy technologies and products.


Report scope


Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.


Global Gene Therapy Partnering Terms and Agreements includes:


  • Trends in gene therapy dealmaking in the biopharma industry since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to over 650 gene therapy deals
  • The leading gene therapy deals by value since 2010
  • Most active gene therapy dealmakers since 2010
  • The leading gene therapy partnering resources


 In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Global Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:


  • In-depth understanding of gene therapy deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 650 actual gene therapy deals entered into by the world’s biopharma companies, together with real world clause examples
  • Full listing of  gene therapy deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading gene therapy deals by value since 2010
  • Identify the most active gene therapy dealmakers since 2010
  • Detailed access to actual gene therapy contracts enter into by the leading bigpharma
  • Insight into the terms included in gene therapy agreement
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Gene Therapy dealmaking


2.1. Introduction
2.2. Gene Therapy partnering over the years
2.3. Most active Gene Therapy dealmakers
2.4. Gene Therapy partnering by deal type
2.5. Gene Therapy partnering by therapy area
2.6. Deal terms for Gene Therapy partnering
2.6.1 Gene Therapy partnering headline values
2.6.2 Gene Therapy deal upfront payments
2.6.3 Gene Therapy deal milestone payments
2.6.4 Gene Therapy royalty rates


Chapter 3 – Leading Gene Therapy deals


3.1. Introduction
3.2. Top Gene Therapy deals by value


Chapter 4 – Most active Gene Therapy dealmakers


4.1. Introduction
4.2. Most active Gene Therapy dealmakers
4.3. Most active Gene Therapy partnering company profiles


Chapter 5 – Gene Therapy contracts dealmaking directory


5.1. Introduction
5.2. Gene Therapy contracts dealmaking directory


Chapter 6 – Gene Therapy dealmaking by technology type




Appendix 1 – Gene Therapy deals by company A-Z

Appendix 2 – Gene Therapy deals by stage of development

Appendix 3 – Gene Therapy deals by deal type

Appendix 4 – Gene Therapy deals by therapy area

Appendix 5 – Deal type definitions

Further reading 


About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

Figure 1: Gene Therapy partnering since 2010
Figure 2: Active Gene Therapy dealmaking activity since 2010
Figure 3: Gene Therapy partnering by deal type since 2010
Figure 4: Gene Therapy partnering by disease type since 2010
Figure 5: Gene Therapy deals with a headline value
Figure 6: Gene Therapy deals with an upfront value
Figure 7: Gene Therapy deals with a milestone value
Figure 8: Gene Therapy deals with a royalty rate value
Figure 9: Top Gene Therapy deals by value since 2010
Figure 10: Most active Gene Therapy dealmakers since 2010

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2seventy bio, 4D Molecular Therapeutics, AavantiBio, AAVLife, AAVnerGene, Abbvie, Abby Grace Foundation, Abeona Therapeutics, Ablynx, Accelerator for Technological Research in Genomic Therapies, Accenture, ACGT, Actinium Pharmaceuticals, Adaptimmune, Addex Therapeutics, Advanced BioScience Laboratories, Advanced Biotherapeutics Consulting, AdVec, Aevitas Therapeutics, Affinia Therapeutics, AffyXell Therapeutics, Agathos Biologics, Agensys, AgeX Therapeutics, Agilis Biotherapeutics, Agrivida, AGTC, AH Diagnostics, Akouos, Alcyone Lifesciences, Alder Biopharmaceuticals, Aldevron, Allegheny General Hospital, Allen Institute for Brain Science, Allergan, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Allogene Therapeutics, AllStripes, Almirall, Alnylam Pharmaceuticals, ALS Finding a Cure Foundation, ALS Therapy Development Institute, Amarantus BioSciences, Amarna Therapeutics, Ambys Medicines, American Association of Neuromuscular & Electrodiagnostic Medicine, American Gene Technologies, American Society of Gene and Cell Therapy, AmerisourceBergen, Amgen, Amicus Therapeutics, AmorChem, Amplimmune, Amsterdam Molecular Therapeutics, AnC Bio, AnGes MG, Angionetics, Annapurna Therapeutics, Apceth, Apollo Therapeutics, Applied DNA Sciences, Applied StemCell, Arbor Biotechnologies, ARCA Biopharma, Ariad Pharmaceuticals, Ark Therapeutics, Arranta Bio, Aruvant Sciences, Ascenion, ASC Therapeutics, Asklepios Biopharmaceutical, Astellas Pharma, ATMPS, Auburn University, Audentes Therapeutics, Autolomous, Avacta, Avalanche Biotechnologies, Avectas, Avellino Labs, AveXis, Avila Therapeutics, Avita Therapeutics, Avrobio, Avvinity Therapeutics, Axovant Gene Therapies, Axxam, Bachmann-Strauss Dystonia & Parkinson Foundation, Baxter International, Bayer, Baylor College, Baylor College of Medicine, B Braun, B Braun CeGaT, Beam Therapeutics, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Benitec Biopharma, Be The Match BioTherapies, BIA Separations, Bill and Melinda Gates Foundation, Bio-Fortune, Bio-Techne, BioCentriq, BioCure, Biogen, BioLife Solutions, BioMarin Pharmaceutical, BioMetrx, Bionic Sight, BioSante Pharmaceuticals, BioSpherix, Biotechnology and Biological Sciences Research Council (BBSRC), Bioverativ, Blackstone, Blood Centers of America, Blood Systems Research Institute, Bluebird Bio, Blueprint Genetics, Boehringer Ingelheim, Bpifrance, Brain Research Through Advancing Innovative NeurotechnologiesInitiative, Brammer Bio, BridgeBio Pharma, Bristol-Myers Squibb, Broad Institute, Brooklyn ImmunoTherapeutics, Butantan Institute, California Institute for Regenerative Medicine, Calimmune, Calyxt, CAMP4 Therapeutics, CANbridge Pharmaceuticals, Cangene, Capsida Biotherapeutics, Casebia Therapeutics, Case Western Reserve University, Case Western Reserve University School of Medicine, Castle Creek Biosciences, Catalent, Cedars-Sinai Health System, Cedars-Sinai Medical Center, CeGaT, Celgene, Celladon, Cell and Gene Therapy Catapult, Cellares, Cellectis Bioresearch, CellGenix, Cell Medica, Celtic Biotech, Cenix BioScience, Centauri Therapeutics, Center for Biomarker Research in Medicine, Centre for Commercialization of Regenerative Medicine (CCRM), Cevec Pharmaceuticals, Chatham Therapeutics, CHDI Foundation, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Hospital of Pittsburgh, Children's Medical Research Institute, Children's Research Institute, Chimeron Bio, Chromatin, Cincinnati Children’s Hospital Medical Center, City of Hope, ClearPoint Neuro, Clearside Biomedical, Cleveland Clinic, Clovis Oncology, CMC Biologics, Coave Therapeutics, Cobra Biologics, CODA Biotherapeutics, Code Biotherapeutics, Codexis, Codiak BioSciences, Cognate BioServices, Cohen-McNiece Foundation, Columbia University, CombiGene, Concord Medical Services Holdings, Copernicus Therapeutics, CPI International, CRISPR Therapeutics, Crucell, CryoPort, CSL Behring, Cure Duchenne, Cure Genetics, Cure Therapeutics, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cytiva, Cytoo, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Decibel Therapeutics, deCODE Genetics, Deep Science Ventures, Deerfield Management, Defense Advanced Research Projects Agency, DefiniGEN, Defyrus, Deloitte, Denovo Biopharma, Diamond Pharma Services, Digna Biotech, Dimension Therapeutics, DiNAQOR, DNA Script, Dnastar, Dr. Reddy's Laboratories, Duke Clinical Research Institute (DCRI), Duke University, DuPont, Dyno Therapeutics, Eden Biodesign, Edimer Pharmaceuticals, Editas Medicine, EGen, Eiger BioPharmaceuticals, ElevateBio, Eli Lilly, Emory University, enGene, Enginasion, Ensoma, Enterprise Partners Venture Capital, EnVivo Pharmaceuticals, Errant Gene Therapeutics, ERS Genomics, Escape Therapeutics, Eunice Kennedy Shriver Institute of Child Health and Human Development, European Commission, European Union, Everads Therapy, Eversana, Evogene, Evotec, Evozyne, Excision BioTherapeutics, Exothera, Expression Therapeutics, Facial Pain Research Foundation, Factor Bioscience, Fate Therapeutics, Federal Ministry of Education and Research (BMBF), FerGene, Ferring Pharmaceuticals, Fibrocell Science, Fidelity Biosciences, FIT Biotech, Five Prime Therapeutics, FKD Therapies, FloDesign Sonics, Fluidigm, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Forge Biologics, Fortress Biotech, Forty Seven, Foundation Fighting Blindness, Foundation Medicine, Foundation to Fight H-ABC, Fovea Pharmaceuticals, Fox Chase Cancer Center, French Muscular Dystrophy Association, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm Diosynth Biotechnologies, Fulcrum Therapeutics, Fundacion Progreso y Salud, Galapagos, GE Healthcare, Gen, Genable Technologies, GenEdit, Genentech, GeneQuine Biotherapeutics, Generation Biotech, Gene Therapy Research Institution, Genethon, Genetic Information Research Institute, Genevant Sciences, Gennao Bio, genOway, Genpharm, Genprex, GenScript Biotech, Gensight Biologics, GenStem Therapeutics, GentiBio, Genzyme, Georgetown University, Georgetown University Medical Center, George Washington University, Geospiza, GeoVax, Ginkgo BioWorks, Gladstone Institutes, GlaxoSmithKline, GlycoBac, Golden Helix, Graphite Bio, Great Ormond Street Hospital (GOSH), Greenlight Biosciences, Gyroscope Therapeutics, Hansa Biopharma, Harvard Medical School, Harvard School of Public Health, Harvard University, HekaBio, Helmholtz Zentrum Munchen, Hemera Biosciences, Hitech Health, Homology Medicines, Horama, Horizon 2020, Horizon Discovery, Hoth Therapeutics, HTG Molecular Diagnostics, Huapont Pharma, Human BioMolecular Research Institute, Humanigen, Iaso Pharmaceuticals, Icagen, Icahn School of Medicine at Mount Sinai, iECURE, IGEA Clinical Biophysics, Immune Pharmaceuticals, Immusoft, Imperial Innovations, Inceptor Bio, Indee Labs, Indivumed, Innovate UK, Innovent Biologics, Institute for Translational Oncology Research, Institute of Child Health, Institute of Molecular and Clinical Ophthalmology Basel, Institut Pasteur, Integrated DNA Technologies, Intellia Therapeutics, Interbiome, International Duchenne Alliance, International Medical Center, Intrexon, iNtRON Biotechnology, Invitae, Ion Channel Innovations, Ipsen, ISIS Innovation, Israeli National Authority for Technological Innovation, Iveric Bio, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Japan Tobacco, Jasper Therapeutics, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, Juno Therapeutics, Juventas Therapeutics, Kadmon Pharmaceuticals, Kangmei Pharma, Kiromic Biopharma, Kite Pharma, Kogenix, Kriya Therapeutics, KWS SAAT, Lab21, LabConnect, Laboratoires Thea, Laboratory Corporation of America, Laboratory of Neurobiology and Gene Therapy, Lacerta Therapeutics, Lawrence Berkeley National Laboratory, Lee Moffitt Cancer Center, Leiden University, Lentigen, Les Laboratoires Servier, LEXEO Therapeutics, Life Edit Therapeutics, Life Technologies Corporation, Liminal BioSciences, LineaRx, Locana, LogicBio Therapeutics, Lonza, Lund University, Lysogene, Mammoth Biosciences, Maria Curie-Sklodowska University, Marken, Maryland Stem Cell Research Fund, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Matica Biotechnology, Mawson Infrastructure, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, McKesson, MD Anderson Cancer Center, MDA Venture Philanthropy, Medac, Medgenics, Medical College of Wisconsin, Medical Research Council, Medical University of South Carolina, Medifocus, MediGene, MedImmune, MED Institute, Medison Pharma, Medtronic, MeiraGTx, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck Serono, Merck Sharpe & Dohme, Mesoblast, Metagenomi, Methodist Hospital Houston, Michael J Fox Foundation, Microsoft, MilliporeSigma, Milo Biotechnology, Miltenyi Biotec, Minaris Regenerative Medicine, Mirum Pharmaceuticals, Mitsubishi Tanabe Pharma, Moderna Therapeutics, MolMed, Monsanto, Morphogenesis, MorphoSys, Muscular Dystrophy Association, Mustang Bio, Myonexus Therapeutics, Myosana Therapeutics, Myriad Genetics, Myrtelle, NanoString Technologies, Nanotechnology Characterization Laboratory, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National Taiwan University Hospital, National University of Ireland, Galway (NUI Galway), Nationwide Children’s Hospital, NecstGen, Neo Gene Pharm, NeuExcell, Neuracle Genetics, Neurocrine Biosciences, Neurogene, Neurophth Therapeutics, New Jersey Innovation Institute, Nightstar Therapeutics, NightstaRx, Nkarta Therapeutics, Noga Therapeutics, North Carolina State University, Northern Biomedical Research, Northwestern University, Novartis, Novartis Institutes for BioMedical Research, Novasep, Novellus Biopharma, Novo Nordisk, Nucleus Biologics, Numerate, Nuron Biotech, Ocugen, Odylia Therapeutics, Ohio State University, Oklahoma University Health Sciences Center, Oncodesign, Oncolys BioPharma, OncoSec Medical, OpGen, Ophthotech, Opus Genetics, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, Orgenesis, Ori Biotech, Oxford BioMedica, Oxford Biomedica Solutions, Oxford Nanopore Technologies, Oxgene, PACA Inovation, Pall Corporation, Panion, Paragon Bioservices, Parent Project Muscular Dystrophy, Passage Bio, Paul Ehrlich Institute, PCT, Peptineo, Perelman School of Medicine, Pfizer, PharmaCell, PhoreMost, Pioneer Hi-Bred, PlantArcBio, PlasmaTech Biopharmaceuticals, PlasmidFactory, Plasticell, Plastomics, Population Diagnostics, Poseida Therapeutics, Precision BioSciences, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, Prostate Cancer Foundation (PCF), Proteacel, Protein Sciences, ProteoNic, Proteonomix, Proteostasis Therapeutics, Provecs Medical, PsiOxus Therapeutics, PTC Therapeutics, Quark Pharmaceuticals, Radboud University Nijmegen Medical Centre, Radient Pharmaceuticals, Ray Therapeutics, Regeneron Pharmaceuticals, Regenxbio, ReGenX Biosciences, Remedium Bio, ReNeuron, Renova Therapeutics, Renovo, Research Development Foundation, Resilience, Response Genetics, RetroSense Therapeutics, Reyon Pharmaceuticals, Roche, Rocket Pharmaceuticals, Roivant Sciences, RoosterBio, SAFC, Saga Investments, SAIC-Frederick, SalioGen Therapeutics, Salk Institute, Sana Biotechnology, Sanford Burnham Institute, Sangamo Therapeutics, Sanofi, San Raffaele Telethon Institute for Gene Therapy, Santen Pharmaceutical, Santhera Pharmaceuticals, Sapreme Technologies, Sarepta Therapeutics, Sartorius, SATT Conectus Alsace, SAVSU Technologies, Scarab Genomics, Scenic Biotech, Schepens Eye Research Institute, Scopus BioPharma, Scottish Enterprise, Scribe Therapeutics, Scriptr Global, Seattle Children's Hospital, Seattle Children's Therapeutics, Seelos Therapeutics, Selecta Biosciences, Sensorion, Senti Biosciences, Sexton Biotechnologies, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shinshu University, Siemens Healthcare, Sigma Life Science, SinoBiotech, Sio Gene Therapies, Sirion Biotech, Sirion Therapeutics, Sirtex Medical, SiSaf, Sitoa, Skyline Therapeutics, Sloning BioTechnology, SmartPharm Therapeutics, Solid Biosciences, SparingVision, Spark Therapeutics, Spooner Girls Foundation, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, StemedicaAnC, Stemedica Internaional, St Jude Medical, StrideBio, Sun Pharmaceutical, SwitchGear Genomics, Symvivo, Synpromics, Synthego, Synthetic Genomics, System Biosciences, T-TOP Clinical Research, Takara Bio, Takeda Pharmaceutical, Talee Bio, Tamid Bio, Tantu Therapeutics, TapImmune, Target ALS Foundation, Taxus Cardium Pharmaceuticals, Taysha Gene Therapies, TeamedOn International, Team Sanfilippo, Temple University, Terumo Blood and Cell Technologies, Teva Pharmaceutical Industries, Tevard Biosciences, Texas A&M Health Science Center, Texas Children’s Hospital, The Cell and Gene Therapy Unit, The Cyprus Institute of Neurology and Genetics, The Parker Institute For Cancer Immunotherapy, Theracell, Theragene Pharmaceuticals, Theravectys, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, TissueGene, Tocagen, Toshiba, Touchlight, Trakcel, TransCytos, Transposagen Biopharmaceuticals, Treeway, Triumvira Immunologics, Tufts Medical Center, Tufts University, Twist Bioscience, Two Blades Foundation, TxCell, Tyris Therapeutics, UCB, UCL Business, Ugichem, UK Cystic Fibrosis Gene Therapy Consortium, Ulster University, Ultragenyx Pharmaceuticals, UNeMed, UniQuest, UniQure, United Cargo, Universite Laval, University College London, University Gottingen, University Hospitals Case Medical Center, University of Alabama, University of Barcelona, University of Basel, University of British Columbia, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Colorado, University of Copenhagen, University of Eastern Finland, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Helsinki, University of Iowa, University of Kentucky, University of Lausanne, University of Leeds, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Medicine and Dentistry of New Jersey, University of Missouri, University of Nebraska, University of North Carolina, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Quebec, University of Rome, University of South Carolina, University of South Florida, University of Texas Southwestern Medical Center, University of Washington, University of Western Australia, University of Wisconsin-Madison, Urovant Sciences, UT Southwestern Medical Center, Vaccine and Gene Therapy Institute of Florida (VGTI-FL), VBL Therapeutics (dba), VectorY Therapeutics, Vertex Pharmaceuticals, VGX International, Vigene Biosciences, ViGeneron, Vineti, Viralgen, Vir Biotechnology, Virginia Catalyst, Virica Biotech, Vision Institute, VITRUVIAN BioMedical, VIVEbiotech, Vivet Therapeutics, Voyager Therapeutics, Vycellix, Wageningen University, Wake Forest University School of Medicine, Wayne State University, Weill Cornell Medical College, Weizmann Institute, Wellcome Trust, Wellcome Trust Sanger Institute, Werum IT Solutions, WhiteLab Genomics, Wilson Wolf, WIRB-Copernicus Group, WuXi Advanced Therapies, Wuxi Apptec Laboratory Services, Xcell Biosciences, Xencor, Xenon Pharmaceuticals, Y-Biologics, Yale University, Yeda Research and Development Company, Yposkesi, Ziopharm Oncology, Zogenix

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.